Satinder Dahiya

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3443760/publications.pdf

Version: 2024-02-01

		759233	1058476
14	1,261	12	14
papers	citations	h-index	g-index

14	14	14	2278
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	HDAC10 deletion promotes Foxp3+ T-regulatory cell function. Scientific Reports, 2020, 10, 424.	3.3	42
2	Histone/protein deacetylase inhibitor therapy for enhancement of Foxp3+ T-regulatory cell function posttransplantation. American Journal of Transplantation, 2018, 18, 1596-1603.	4.7	53
3	Utility of IL-2 Complexes in Promoting the Survival of Murine Orthotopic Forelimb Vascularized Composite Allografts. Transplantation, 2018, 102, 70-78.	1.0	10
4	Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. Cell Metabolism, 2017, 25, 1282-1293.e7.	16.2	741
5	Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function. Scientific Reports, 2017, 7, 8626.	3.3	64
6	Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3 + T-regulatory Cell Function and Promotes Antitumor Immunity. EBioMedicine, 2016, 13, 99-112.	6.1	86
7	CCAAT Enhancer Binding Protein and Nuclear Factor of Activated T Cells Regulate HIV-1 LTR via a Novel Conserved Downstream Site in Cells of the Monocyte-Macrophage Lineage. PLoS ONE, 2014, 9, e88116.	2.5	20
8	Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT/enhancer binding protein site I. Virology Journal, 2014, 11, 92.	3.4	20
9	Genetic Variation and HIV-Associated Neurologic Disease. Advances in Virus Research, 2013, 87, 183-240.	2.1	25
10	Impact of Tat Genetic Variation on HIV-1 Disease. Advances in Virology, 2012, 2012, 1-28.	1.1	58
11	Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic development. Journal of General Virology, 2012, 93, 1151-1172.	2.9	8
12	Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies. Journal of Virological Methods, 2010, 167, 10-16.	2.1	32
13	An Envelope Domain IIIâ€“based Chimeric Antigen Produced in Pichia pastoris Elicits Neutralizing Antibodies Against All Four Dengue Virus Serotypes. American Journal of Tropical Medicine and Hygiene, 2008, 79, 353-363.	1.4	69
14	An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. American Journal of Tropical Medicine and Hygiene, 2008, 79, 353-63.	1.4	33